-
In this month’s STAT Expert Advantage call,
@adamfeuerstein talks$NVS' Adakveo and$GBT's Oxbryta with Duke University’s director of the Adult Sickle Cell program. Sign up here: https://buff.ly/2tsCqo5#STATExpertAdvantage pic.twitter.com/G0SiuJmmRz
-
Starting now a doc call with
@damiangarde leading "Reviewing Novel Mechanisms in Depression: SAGE-217 in MDD, Axsome Therapeutics' AXS-05, and Recently Approved Esketamine From JNJ." https://slingshotinsights.com/projects/1130#StatExpertAdvantage -
HAPPENING NOW:
@damiangarde hosts our next conference call reviewing novel mechanisms in#depression treatments. Join STAT Expert Advantage to tune in: https://buff.ly/2OJYph3#STATExpertAdvantage -
STAT’s
@adamfeuerstein will host our September conference call on the future of the lung cancer treatment market. Join STAT Expert Advantage to tune in: https://buff.ly/2NoRZGb#STATExpertAdvantage#lungcancerpic.twitter.com/PdHGYKPJe2
-
TOMORROW: Join
@damiangarde as he hosts our next STAT Expert Advantage conference call on the Sickle Cell treatment landscape. Save your spot here: https://buff.ly/2Y7zx5C#STATExpertAdvantage pic.twitter.com/tca0yCuhLX
-
Don't miss our post ASCO Expert Call Today at 3pm ET led by
@adamfeuerstein$MRK ,$AMGN ,$IOVA ,$NKTR ,$NVS ,$AZN ,$MRTX ,$BPMC http://ddil.si/c7axk5rw/#statexpertadvantage
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.